Sodium/glucose co-transporter 1 expression increases in human diseased prostate

Journal of Cancer Science and Therapy

Volumn 4, Issue 9, 2012, Pages 306-312

  Blessing, Alicia ^a   Xu, Lei ^a   Gao, Guang ^a   Bollu, Lakshmi Reddy ^a   Ren, Jiangong ^a   Li, Hangwen ^b   Wu, Xuefeng ^a   Su, Fei ^a   Huang, Wei Chien ^c   Hung, Mienchie ^c,d   Huo, Lei ^d   Palapattu, Ganesh S ^b   Weihua, Zhang ^a  

^a University of Houston   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Benign prostatic hyperplasia; Prostate; Prostate cancer; SGLT1

Indexed keywords

POLYCLONAL ANTIBODY; SODIUM GLUCOSE COTRANSPORTER 1; TENASCIN;

ARTICLE; BASAL CELL; CANCER CELL; CONTROLLED STUDY; GENE OVEREXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; STROMA CELL; UPREGULATION; WESTERN BLOTTING;

EID: 84867542076     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000159     Document Type: Article

References (39)

1. Zhao FQ, Keating AF (2007) Functional properties and genomics of glucose transporters. Curr Genomics 8: 113-128.
2. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91: 733-794.
3. Castaneda-Sceppa C, Castaneda F (2011) Sodium-dependent glucose transporter protein as a potential therapeutic target for improving glycemic control in diabetes. Nutr Rev 69: 720-729.
4. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, et al. (2003) A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci U S A 100: 11753-11758.
5. Vannucci SJ, Seaman LB, Vannucci RC (1996) Effects of hypoxia-ischemia on GLUT1 and GLUT3 glucose transporters in immature rat brain. J Cereb Blood Flow Metab 16: 77-81.
6. Peansukmanee S, Vaughan-Thomas A, Carter SD, Clegg PD, Taylor S, et al. (2009) Effects of hypoxia on glucose transport in primary equine chondrocytes in vitro and evidence of reduced GLUT1 gene expression in pathologic cartilage in vivo. J Orthop Res 27: 529-535.
7. Gamelli RL, Liu H, He LK, Hofmann CA (1996) Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 59: 639-647.
8. Mann GE, Yudilevich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183-252.
9. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202: 654-662.
10. Hanabata Y, Nakajima Y, Morita K, Kayamori K, Omura K (2012) Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 100: 156-163.
11. Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, et al. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol 28: S197-S203.
12. Casneuf VF, Fonteyne P, Van Damme N, Demetter P, Pauwels P, et al. (2008) Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest 26: 852-859.
13. Lai B, Xiao Y, Pu H, Cao Q, Jing H, et al. (2012) Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 285: 1455-1461.
14. Costello LC, Franklin RB (2000) The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 59: 269-282.
15. Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, et al. (2011) Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/ CT. Ann Nucl Med 26: 138-145.
16. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, et al. (2006) Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 207: 614-627.
17. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, et al. (2011) Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem 113: 553-562.
18. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, et al. (2012) Na(+)- D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61: 187-196.
19. Lee WS, Kanai Y, Wells RG, Hediger MA (1994) The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269: 12032-12039.
20. Schauer IG, Rowley DR (2011) The functional role of reactive stroma in benign prostatic hyperplasia. 82: 200-210.
21. Tuxhorn JA, Ayala GE, Rowley DR (2001) Reactive stroma in prostate cancer progression. J Urol 166: 2472-2483.
22. Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9: 230-234.
23. Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, et al. (2011) Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci 26: 1214-1218.
24. Kasturi S, Russell S, McVary KT (2006) Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7: 288-292.
25. Schöder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34: 274-292.
26. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, et al. (2008) Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 68: 1743-1752.
27. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, et al. (2003) Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9: 4792-4801.
28. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923.
29. Avril N, Dambha F, Murray I, Shamash J, Powles T, et al. (2010) The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/ computed tomography in urological cancers. Int J Urol 17: 501-511.
30. Yang W, Xia Y, Ji H, Zheng Y, Liang J, et al. (2011) Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480:118-122.
31. Maissel A, Marom M, Shtutman M, Shahaf G, Livneh E (2006) PKCeta is localized in the Golgi, ER and nuclear envelope and translocates to the nuclear envelope upon PMA activation and serum-starvation: C1b domain and the pseudosubstrate containing fragment target PKCeta to the Golgi and the nuclear envelope. Cell Signal 18:1127-1139.
32. Wang SC, Lin JK, Wang HS, Yang SH, Li AF (2010) Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 25: 1185-1191.
33. Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, et al. (2008) Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J Surg Oncol 97: 544-550.
34. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801-3813.
35. Ibrahim GK, Kerns BJ, MacDonald JA, Ibrahim SN, Kinney RB, et al. (1993) Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149: 170-173.
36. De Miguel P, Royuela, Bethencourt R, Ruiz A, Fraile B, et al. (1999) Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11: 722-727.
37. Leav I, McNeal JE, Ziar J, Alroy J (1998) The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions. Hum Pathol 29: 668-675.
38. Sherwood ER, Lee C (1995) Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 13: 290-296.
39. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, et al. (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393.